---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-060124"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2026-09-02T20:29:56+00:00"
generated_at: "2026-09-02T20:31:44.397917+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Senti Bio receives Nasdaq delisting notices; amends financing, $2M NSG note sale

## Summary
- Nasdaq: bid price below $1.00 for 30 days; 180-day cure period to Feb 23, 2027.
- Stockholders' equity deficit of $3.4M vs $2.5M requirement; plan due Oct 11, 2026.
- Amendment authorizes $2.0M third-tranche note sale to NSG BioInnovation Fund.
- NSG purchase satisfies Celadon's remaining note purchase obligation under Merger Agreement.
- Contingent value right up to $60M tied to SENTI-202 milestones in proposed merger.

## SEC filing metadata
- accession: 0001628280-26-060124
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2026-09-02T20:29:56+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000162828026060124/0001628280-26-060124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000162828026060124/snti-20260827.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-060124
- JSON: https://secwatch.observer/filing/0001628280-26-060124.json
- Plain text: https://secwatch.observer/filing/0001628280-26-060124.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.